Summary
This article gives a short historical account of the events and circumstances that led to the discovery of the occurrence of dopamine (DA) in the brain and its deficiency in Parkinson’s disease (PD). Some important consequences, for both the basic science and the patient, of the work on DA in the PD brain are also highlighted.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anden NE, Carlsson A, Dahlström A, Fuxe K, Hillarp NA, Larsson K (1964) Demonstration and mapping out of nigro-striatal dopamine neurons. Life Sci 3: 523–530
Barbeau A, Murphy GF, Sourkes TL (1961) Excretion of dopamine in diseases of basal ganglia. Science 133: 1706–1707
Barbeau A, Sourkes TL, Murphy GF (1962) Les catécholamines dans la maladie de Parkinson. In: deAjuriaguerra (ed) Monoamines et système nerveux centrale. Georg, Genève and Masson, Paris, pp 247–262
Bertler Å, Rosengren E (1959a) Occurrence and distribution of dopamine in brain and other tissues. Experientia 15: 10–11
Bertler Å, Rosengren E (1959b) On the distribution in brain monoamines and of enzymes responsible for their formation. Experientia 15: 382–383
Birkmayer W, Hornykiewicz O (1961) Der L-ioxyphenylalanin (=DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787–788
Birkmayer W, Hornykiewicz O (1962) Der L-Dioxyphenylalanin (=DOPA)-Effekt beim Parkinson-Syndrom des Menschen: zur Pathogenese und Behandlung der Parkinson-Akinese. Arch Psychiat Nervenkr 203: 560–574
Blaschko H (1957) Metabolismand storage of biogenic amines. Experientia 13: 9–12
Carlsson A (1964) Functional significance of druginduced changes in brain monoamine levels. In: Himwich HE, Himwich WA (eds) Biogenic amines. Elsevier, Amsterdam, pp 9–27 (Progr Brain Res 8)
Carlsson A (1965) Drugs which block the storage of 5-hydroxytryptamine and related amines. In: Eichler O, Farah A (eds) 5-Hydroxytryptamine and related indolealkylamines. Springer, Berlin Heidelberg New York, pp 529–592 (Handb Exp Pharmacol vol 19)
Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxy-tryptophan as reserpine antagonists. Nature 180: 1200
Carlsson A, Lindqvist M, Magnusson T, Waldeck B (1958) On the presence of 3-hydroxy-tyramine in brain. Science 127: 471
Cotzias GC, Van Woert MH, Schiffer IM (1967) Aromatic amino acids and modification of Parkinsonism. N Engl J Med 276: 374–379
Dahlström A, Fuxe K (1964) Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 62[Suppl 232]
Denny-Brown D (1962) The basal ganglia and their relation to disorders of movement. Oxford University Press, Oxford
Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38: 1236–1239
Hardy J, Langston WJ (2004) How many pathways are there to nigral death? Ann Neurol 56: 316–318
Hassler R (1938) Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol 48: 387–476
Hassler R (1967) Private communication to O. Hornykiewicz. Letter dated February 9, 1967
Holtz P, Balzer H, Westermann E, Wezler E (1957) Beeinflussung der Evipannarkose durch Reserpin, Iproniazid und biogene Amine. Arch Exp Path Pharmakol 231: 333–348
Holzer G, Hornykiewicz O (1959) Über den Dopamin-(Hydroxytyramin-) Stoffwechsel im Gehirn der Ratte. Naunyn Schmiedebergs Arch Exp Path Pharmacol 237: 27–33
Hornykiewicz O (1958) The action of dopamine on the arterial pressure of the guinea pig. Br J Pharmacol 13: 91–94
Hornykiewicz O (1963) Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in the Substantia nigra des normalen und Parkinsonkranken Menschen. Wien Klin Wochenschr 75: 309–312
Hornykiewicz O (2001a) Brain dopamine: a historical perspective. In: Di Chiara G (ed) Dopamine in the CNS I. Springer, Berlin Heidelberg, pp 1–22 (Handb Exp Pharmacol vol 154/I)
Hornykiewicz O (2001b) How L-DOPA was discovered as a drug for Parkinson’s disease 40 years ago. Wien Klin Wochenschr 113: 855–862
Hornykiewicz O (2002a) Dopamine and Parkinson’s disease. A personal view of the past, the present, and the future. Adv Neurol 86: 1–11
Hornykiewicz O (2002b) Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord 17: 501–508
Jasper HH (1970) Neurophysiological mechanisms in parkinsonism. In: Barbeau A, McDowell FH (eds) L-Dopa and parkinsonism. FA Davis, Philadelphia, pp 408–411
Jung R, Hassler R (1960) The extrapyramidal motor systems. In: Field J, Magoun HW, Hall VE (eds) Handbook of Physiology, sect 1. Neurophysiology, vol II. American Physiological Society, Washington DC, pp 863–927
Montagu KA (1957) Catechol compounds in rat tissues and in brains of different animals. Nature 180: 244–245
Poirier LJ, Sourkes TL (1965) Influence of the substantia nigra on the catecholamine content of the striatum. Brain 88: 181–192
Raab W, Gigee W (1951) Concentration and distribution of “encephalin” in the brain of humans and animals. Proc Soc Exp Biol Med 76: 97–100
Sano I (1962) Private communication to O. Hornykiewicz. Letter dated March 20, 1962
Sano I (2000) Biochemistry of the extrapyramidal system. Parkinsonism Relat Disord 6: 3–6
Sano I, Gamo T, Kakimoto Y, Taniguchi K, Takesada M, Nishinuma K (1959) Distribution of catechol compounds in human brain. Biochim Biophys Acta 32: 586–587
Sourkes TL (2000) How dopamine was recognised as a neurotransmitter: a personal view. Parkinsonism Relat Disord 6: 63–67
Vogt M (1952) Die Verteilung pharmakologisch aktiver Substanzen im Zentralnervensystem. Klin Wochenschr 30: 907–908
Vogt M (1954) The concentration of sympathin in different parts of the central nervous system under normal conditions and after the administration of drugs. J Physiol 123: 451–481
Vogt M (1973) Functional aspects of the role of catecholamines in the central nervous system. Br Med Bull 29: 168–172
Ward AA (1970) Physiological implications in the dyskinesias. In: Barbeau A, McDowell FH (eds) L-Dopa and parkinsonism. FA Davis, Philadelphia, pp 151–159
Weber G (1952) Zum Cholinesterasegehalt des Gehirns bei Hirntumoren und bei Parkinsonismus. Bull Schweiz Akad Med Wiss 8: 263–268
Weil-Malherbe H, Bone AD (1957) Intracellular distribution of catecholamines in the brain. Nature 180: 1050–1051
Weil-Malherbe H, Bone AD (1958) Effect of reserpine on the intracellular distribution of catecholamines in the brain stem of the rabbit. Nature 181: 1474–1475
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag
About this paper
Cite this paper
Hornykiewicz, O. (2006). The discovery of dopamine deficiency in the parkinsonian brain. In: Riederer, P., Reichmann, H., Youdim, M.B.H., Gerlach, M. (eds) Parkinson’s Disease and Related Disorders. Journal of Neural Transmission. Supplementa, vol 70. Springer, Vienna . https://doi.org/10.1007/978-3-211-45295-0_3
Download citation
DOI: https://doi.org/10.1007/978-3-211-45295-0_3
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-28927-3
Online ISBN: 978-3-211-45295-0
eBook Packages: MedicineMedicine (R0)